Nagio Takigawa

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer

K. Kiura, Hideko Isozaki, Nagio Takigawa, 2015, Cancers.

Liposomal Delivery of MicroRNA-7–Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells

Kenji Shimizu, K. Kiura, M. Tanimoto, 2011, Molecular Cancer Therapeutics.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

Point mutation of K-ras gene in cisplatin-induced lung tumours in A/J mice.

Toshiaki Okada, Masahiro Tabata, K. Kiura, 2007, Lung cancer.

Guidelines for the use and interpretation of assays formonitoring autophagy (3rd edition)

Sangeeta Khare, Xin Qi, Ying Wang, 2016 .

Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer

Motowo Nakajima, William Seibel, Sandra Nelson, 2013, PloS one.

Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.

Keitaro Matsuo, Masahiro Tabata, Susumu Kanazawa, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.